skip to main content
Idioma:

Prognostic Significance of the Lost of a Major Molecular Response In Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (Ph+CML)

García-Gutiérrez, J. Valentin ; Herrera, Pilar ; Jimenez-Rolando, Marta ; Tenorio, María ; Calbacho, María ; Blanchard, M. Jesús ; Rey, Maria Dolores ; Ramos, Paloma ; Ramos, ML ; Lopez, Javier

Blood, 2010-11, Vol.116 (21), p.3435-3435 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
  • Título:
    Prognostic Significance of the Lost of a Major Molecular Response In Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia (Ph+CML)
  • Autor: García-Gutiérrez, J. Valentin ; Herrera, Pilar ; Jimenez-Rolando, Marta ; Tenorio, María ; Calbacho, María ; Blanchard, M. Jesús ; Rey, Maria Dolores ; Ramos, Paloma ; Ramos, ML ; Lopez, Javier
  • É parte de: Blood, 2010-11, Vol.116 (21), p.3435-3435
  • Descrição: Abstract 3435 Albeit of well-known, dramatic improvements, there remain some questions to be solved around Ph+CML in treatment with tyrosine kinase inhibitors (TKI). Among these, the significance of the amount of minimal residual disease (MRD) measured by RT-PCR. For instance, loss of a so-called major molecular response (MMR) is claimed to be a Òsuboptimal responseÓ and following the ELN recommendations, a change in treatment should be considered in these patients. To evaluate the relevance of a loss of MMR in patients with complete cytogenetic response (CCR). We have analized 81 patients treated with imatinib for CML in chronic phase with a median follow up of 66 months. 36 patients started imatinib after interferon failure and 45 as front line therapy. Major Molecular Response (MMR; BCR-ABL/ABL ratio<0.1% IS) at any time was achieved by 63 patients. 22 patients (34%) lost MMR (documented al least twice). The risk of losing MMR was higher in late MMR (>18 months) compared with those cases whose MMR came much earlier (<18 months): 70% vs 18% (p=. 000). We have found no correlation among the lost of MMR and classical prognostic factors (Sokal-Index, mutations at the TK domain or imatinib plasma levels). Of these 22 patients, 7 (32 %) recovered MMR later with no therapy changes, 8 (36%) experienced fluctuations in the BCR-ABL transcript-levels without losing CCR, 4 (19%) did not attain a MMR but remained in stable CRR, and 3 (13%) lost CCR. These regained MMR after being treated on second generation TKI. The results show how the stability of the early MMR is greater than late MMR (table1). In our experience, one third of the patients who lost MMR recovered it later on the same treatment. And only 13% went on to treatment failure. Perhaps some similar cases (after first losing MMR) should be closely monitored before a change in treatment. Also of note is, of course regarding only our experience, that the risk of a loss of MMR seems to be maximal in patients who achieve a late MMR. Table 1Evolution of patients after lossing MMREarly MMR (n= 9)Late MMR (n=13)Recover MMR45% (4)23% (3)Fluctuations33% (3)38% (5)Remained in Suboptimal Response11% (1)23% (3)Lost CCR11% (1)15% (2) No relevant conflicts of interest to declare.
  • Editor: Elsevier Inc
  • Idioma: Inglês
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.